Allogene Therapeutics
ALLO
182 hedge funds and large institutions have $2.25B invested in Allogene Therapeutics in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 82 increasing their positions, 30 reducing their positions, and 27 closing their positions.
173% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 30
52% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 27
8% more funds holding
Funds holding: 169 → 182 (+13)
0% more call options, than puts
Call options by funds: $4.69M | Put options by funds: $4.68M
1.83% less ownership
Funds ownership: 62.83% → 61% (-1.8%)
28% less capital invested
Capital invested by funds: $3.12B → $2.25B (-$868M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$64.8M |
| 2 |
Morgan Stanley
New York
|
+$29.5M |
| 3 |
BlackRock
New York
|
+$21.4M |
| 4 |
SC
Sessa Capital
New York
|
+$21.4M |
| 5 |
Renaissance Technologies
New York
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$207M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$87.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$40.4M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$25.3M |
| 5 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$23.9M |
ALLO Hedge Fund Activity: Q2 2021 in Review
182 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2021, worth a combined $2.25B — down 28% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ALLO positions and 27 closed out — a net gain of 14 holders — while 82 added to existing stakes and 30 trimmed.
The largest buyer was Primecap Management, adding an estimated $64.8M. The largest seller was Capital Research Global Investors, cutting an estimated $207M.
- 182 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2021, up from 169 in Q1 2021.
- Funds reported $2.25B of Allogene Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
- 41 funds opened new Allogene Therapeutics positions in Q2 2021 and 27 closed out, a net change of +14 holders.
- The largest Allogene Therapeutics buyer in Q2 2021 was Primecap Management, an estimated $64.8M added.
- The largest Allogene Therapeutics seller in Q2 2021 was Capital Research Global Investors, an estimated $207M sold.
Based on aggregated 13F filings for Q2 2021.